Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I, Double-Blind, Randomized, Placebo-Controlled, Safety and Pharmacokinetic Dose-Escalation Study of a Single Intravenous Administration of MDX-1106, a Fully Human Monoclonal Antibody to PD-1, in Subjects With Active Hepatitis C Genotype 1 Infection

Next Previous
Search
Trial Profile

Phase I, Double-Blind, Randomized, Placebo-Controlled, Safety and Pharmacokinetic Dose-Escalation Study of a Single Intravenous Administration of MDX-1106, a Fully Human Monoclonal Antibody to PD-1, in Subjects With Active Hepatitis C Genotype 1 Infection

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2009

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Bristol-Myers Squibb; Medarex

    • Most Recent Events

    • 28 Oct 2009 Actual end date (1 Oct 2009) added as reported by ClinicalTriasl.gov
    • 28 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 31 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top